Dare Bioscience
DARE
14 hedge funds and large institutions have $1.04M invested in Dare Bioscience in 2017 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
8% more funds holding
Funds holding: 13 → 14 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.12% less ownership
Funds ownership: 8.12% → 7.99% (-0.12%)
37% less capital inflows, than outflows
Capital inflows: $49.3K | Capital outflows: $77.7K
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$30.2K |
| 2 |
Panagora Asset Management
Boston,
Massachusetts
|
+$15.6K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.25K |
| 4 |
Washington Trust Bank
Spokane,
Washington
|
+$64 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$57K |
| 2 |
Goldman Sachs
New York
|
-$6.75K |
| 3 |
Polaris Venture Management Co V
Boston,
Massachusetts
|
-$6.72K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$4K |
| 5 |
Sterling Investment Advisors (Pennsylvania)
Berwyn,
Pennsylvania
|
-$2K |
DARE Hedge Fund Activity: Q4 2017 in Review
14 of the 4,420 institutional investors tracked by Wall St. Rank reported a position in Dare Bioscience (DARE) for Q4 2017, worth a combined $1.04M — down 32% from $1.53M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new DARE positions and 3 closed out — a net gain of 1 holder — while 1 added to existing stakes and 4 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $30.2K. The largest seller was Millennium Management, exiting entirely with an estimated $57K sold.
- 14 institutional investors held Dare Bioscience (DARE) as of Q4 2017, up from 13 in Q3 2017.
- Funds reported $1.04M of Dare Bioscience stock for Q4 2017, down 32% quarter-over-quarter.
- 4 funds opened new Dare Bioscience positions in Q4 2017 and 3 closed out, a net change of +1 holder.
- The largest Dare Bioscience buyer in Q4 2017 was Citadel Advisors, an estimated $30.2K added.
- The largest Dare Bioscience seller in Q4 2017 was Millennium Management, an estimated $57K sold.
Based on aggregated 13F filings for Q4 2017.